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CHRONIC OBSTRUCTIVE PULMONARY 
DISEASE (COPD) 
Etiology, prevalence and types 
COPD is a major cause of mortality and morbidity 
worldwide and poses an increasing global healthcare 
problem (1). The definition of COPD recognises the 
“abnormal”, exaggerated or amplified inflammatory 
response in the lung and systemically to cigarette smoking 
and noxious pollutions (2). The pattern of inflammation 
involves recruitment of lymphocytes, macrophages and 
neutrophils, as well as activation and damage to structural 
cells following the release of inflammatory chemokines 
and cytokines (2–5). In the Western world, the major driver 
of disease is cigarette smoke (CS) which is a complex 
mixture of organic chemicals, heavy metals and reactive 
oxygen species (ROS) (6–11). Importantly, Sopori (12) 
highlighted that chronic inhalation of cigarette smoke can 
modulate both innate and adaptive immune responses. 
Moreover, it has been speculated that many of the health 
consequences of chronic cigarette smoking might be due to 
its adverse effects on the immune system (13). Many 
inflammatory cells and their mediators, both of the innate 
and adaptive immune system, participate in the 
inflammatory processing of COPD. Macrophages, 
neutrophils and CD8+ T cells are the cells usually 
considered the prime effector cells in pathogenesis of 
COPD (14), but recently DCs have been suggested to be a 
potentially important new player/orchestrator of the 
pattern of inflammation that characterizes COPD (15, 16). 
The Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) and American Thoracic Society 
(ATS)/European Respiratory Society  (ERS) COPD 
guidelines have defined COPD as a preventable and 
treatable disease characterized by airflow limitation that is 
partially reversible (17, 18).  It is likely that CS-induced 
inflammation is responsible, at least in part, for this airflow 
limitation.  Multiple intracellular signaling events occur by 
CS, which ultimately leads to the synthesis and release of 
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pro-inflammatory mediators, such as interleukin-8 (IL-
8)/CXCL8, IL-1β, and tumor necrosis factor-α TNF-α) (19, 
20).  CXCL8 levels, for example, are markedly increased in 
induced sputum of patients with COPD and this increase 
correlates with the increased proportion of neutrophils (22-
26).  
Besides CXCL8 and other inflammatory cytokines and 
chemokines, there is evidence for enhanced presence of 
markers of oxidative stress in COPD including nitric oxide 
(NO) (27), hydrogen peroxide (27) and lipid peroxidation 
products (28, 29) in COPD patients. NO is generated in 
COPD from the enzyme inducible NO synthase (NOS2), 
which is expressed in macrophages and lung parenchyma 
of patients with COPD, particularly in patients with severe 
disease (30).  In addition, there is increased expression of 
neuronal NOS (NOS1) in these patients (31). NO is 
markedly increased in exhaled breath of patients with mild 
asthma, reflecting the inflammatory process in the airways 
(31) but in patients with COPD exhaled NO levels are little 
raised above normal (32, 33) but are more clearly increased 
during exacerbations (32).  This may reflect formation of 
nitrotyrosine adducts which are markedly increased in 
COPD (14). 
  
COPD in Never Smokers 
Since the 1950s tobacco smoking has been linked to 
COPD (17) and smoking has long been widely considered 
as the single most important risk factor for COPD.  A great 
percentage of COPD mortality and morbidity in both 
genders can be attributed to cigarette smoking (14).  
Because of such well-association, a number of studies have 
concentrated on the role of smoking in COPD, focusing 
only on smokers, in particular, those with at least 20 pack-
years of cigarette smoking exposure (34).   
However, published data in recent years demonstrate a 
significant prevalence of COPD among never smokers.  
Increasing evidence suggests that non-smokers may 
account for between one fourth and one third of all COPD 
cases in contrast to the 50-70% whose COPD is smoking- 
related (37-40).  This prevalence varies across nations in 
both developed and developing regions and mainly relates 
to exposure to indoor pollution (35). However, little is 
known about the pathological features and molecular 
mechanisms underlying this type of COPD in non-smokers 
(36).   
Recognizing the etiology of generalized 
bronchopulmonary lesions in nonsmokers with an 
unknown history of previous exposure is a challenge to 
physicians and researchers.  Indoor air pollution includes 
coal and biomass fuel combustion, as well as ETS, which is 
one of the major etiologies for non-cigarette smoking-
induced COPD (41-44). Biomass fuels such as wood, 
charcoal, crops, twigs, dry grass and dung are widely used 
for cooking or heating in low-income countries (43).  
According to the World Health Organization WHO) 
estimation, approximately 50% of all households and 90% 
of rural households utilize biomass or coal fuels for 
cooking and heating worldwide (43).  This suggests that 
about three billion people worldwide are exposed to 
smoke produced from biomass or coal fuel burning (43).   
In China, approximately 60% of rural households use 
biomass fuel for cooking and 31% use coal fuel (44).  A 
recent investigation of 13 urban and rural areas in China 
demonstrated that 44.6% and 73.2% of non-smokers were 
exposed to biomass and coal smoke respectively, and 40% 
had poor ventilation in the kitchen (45).  This compares 
with the first study detailing the bronchopulmonary 
characteristics of 10 Iranian women who were exposed to 
the indoor smoke published by Amoli in 1998 (46).  
There may be some variability in the presentation of 
COPD in patients who are never smokers but exposed to 
biomass smoke.  In a large epidemiological study in China 
the prevalence of COPD in non-smokers was 5.2%.  
Exposure to biomass smoke and the presence of poor 
ventilation in the kitchen were independently associated 
with a higher risk of COPD among non-smokers. 
Interestingly, non-smokers with COPD were less likely to 
present with chronic productive coughs and lower BMI, 
while more likely to have received a physician diagnosis of 
asthma and respiratory diseases in childhood, than 
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smokers with COPD and may therefore have a distinct 
profile from that of smokers with COPD (47). 
Overall, females older than 55, with a previous history 
of a respiratory disease and without expectoration or 
wheezing predominate in populations characterized as 
having COPD despite being never smokers (48). 
Furthermore, charcoal workers exposed to wood smoke 
have increased respiratory symptoms and decreased 
pulmonary function (49).  
A Brazilian study of 1402 subjects has reported that the 
amount of particulate matter less than 2.5μm in diameter 
(PM2.5), whether from indoor or outdoor biomass fuel, 
was associated with worse lung function, greater 
respiratory symptoms and the development of COPD. 
These effects were associated with the duration and 
magnitude of biomass exposure and were exacerbated by 
tobacco smoke.  This was not seen in individuals from the 
same community exposed to liquefied petroleum gas (50).  
In a similar manner, Turkish women from rural areas 
exposed to biomass fumes were more likely to suffer from 
chronic bronchitis and COPD than women from urban 
areas even though the incidence of cigarette smoking was 
much greater in the urban population (51).  Furthermore, 
in a group of 561 females from Isfahan in Iran, age, 
childhood pulmonary infection, bread baking, carpet 
weaving and use of biomass fuels were all significant risk 
factors for chronic bronchitis with a reduced risk if using 
kerosene or gas.  Only 7 women were current or ex-
smokers (52). Importantly, the concentration of respirable 
particulate matter was up to 4-fold more concentrated 
indoors than outdoors. This confirmed the earlier data 
from Amoli in 1998 (46).  
It has been suggested that the majority of serious effects 
on morbidity and mortality related to air pollution occur 
via interactions with respiratory infection (53).  However, 
the mechanisms underlying the relationship between 
infection and the development of lower airway symptoms 
after air pollution exposure are not fully understood. 
Oxidant pollutant exposures have the potential to 
exacerbate the inflammatory effects of virus infections in 
the lower airway, especially in individuals with pre-
existing lung disease (53). 
The prevalence of respiratory illnesses and symptoms 
was considerably higher in mud and brick houses when 
compared with concrete houses, and higher in those living 
on hills and in rural areas when compared with flatland 
and urban areas. Regalado et al.(54) reported that women 
who used a stove burning biomass fuel in Solis, close to 
Mexico City, showed moderate airflow obstruction with 
COPD at stage GOLD II,. In addition, Orozco-Levi et al. 
(55) reported that most of their study population of non-
smoking women with COPD in Barcelona Spain) between 
2000 and 2003 were exposed to wood and charcoal smoke 
during their childhood and youth, but remained free of 
exposure for more than 25 years prior to presenting with 
symptoms of the disease.  The risk of developing COPD 
was greatest if subjects were exposed to both wood and 
charcoal (54).   
Furthermore, the incidence of non-smoking COPD 
(GOLD stage 2) in Northern Sweden reached 7% in almost 
2000 subjects studied and was associated with increasing 
age but not sex or exposure to environmental tobacco 
smoke.  Of those subjects with airway obstruction as 
defined by GOLD, 14% of men and 27% of women had 
never smoked (56). The authors did not report on biomass 
or wood smoke exposure in these subjects.  Although use 
of biomass fuel for cooking is not common in Western 
Europe, exposure to air pollutants in workplaces such as 
farming, coal mining, construction, gold mining, plastic, 
textile, rubber, leather manufacturing, manufacture of food 
products and automotive repair have been shown to be 
important and may account for the incidence of COPD in 
non-smokers in the UK and other parts of Europe (57). 
 
Is the immunological profile of COPD due 
to indoor pollution the same as that due to 
cigarette smoke? 
The immune cells involved in COPD development and 
progression have been summarized in several excellent 
reviews (58, 59).  Innate immune cells such as epithelial 
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cells and macrophages are activated by cigarette smoke, 
either directly or indirectly through pathogen-associated 
molecular patterns (PAMPs), following binding to pattern 
recognition receptors such as Toll-like receptors.  The 
adaptive immune system is also activated in response to 
cigarette smoke and involves stimulation of specific T 
helper subsets such as Th1 and Th17 CD4+ T cells, 
cytotoxic CD8+ cells and enhanced B-cell responses.  The 
persistent inflammatory insult from continued smoking 
leads to the development of lymphoid follicles.  More 
recently, the role of activated dendritic cells in this process 
has become clear (59).   
Cosio and colleagues have defined a 3 step process by 
which the cigarette smoke-activated immune system 
produces the classic pathological symptoms of COPD (58).  
In the initial innate immune response, epithelial cells 
which are damaged by cigarette smoke release a number of 
danger signals (PAMPs) that can result in the enhanced 
expression of chemokines and cytokines including CXCL8, 
IL-1β, TNFα, CXCL10 and GM-CSF.  Damaged epithelial 
cells can also release proteases such as elastin and MMPs, 
growth factors and other matrix modifying enzymes that 
can further the release of TLR ligands providing a feed-
forward inflammatory drive and enhanced tissue injury 
and small airway remodelling.  During this process, 
dendritic cells that have processes that interdigitate 
throughout the epithelial barrier, are activated and they 
migrate to local lymph nodes where they are able to 
activate T cell proliferation.  Production of TLR ligands 
within the airways also leads to direct stimulation of 
dendritic cells resulting in enhanced expression of the cell 
surface markers CD80 and CD86 and a local inflammatory 
environment conducive to T cell antigen presentation and 
proliferation of Th1, Th17 and cytolytic CD8+ T cells.  The 
role of Treg cells and γδ CD8+ T cells in limiting this 
progression can be overcome by the presence of IL-6 which 
is secreted from activated dendritic cells.   
In more severe disease, tolerance is lost and an 
adaptive immune response develops in the lung.  This is 
linked to the additional activation of IgG-producing B cells 
and the presence of increased oxidative and nitrosative 
stress and proteinases leading to the classical pathological 
features of COPD namely cell necrosis and apoptosis, 
immune and complement deposition, tissue injury with 
airway remodeling and emphysema. 
To date, there is little available data on the 
immunologic response to indoor smoke in the literature 
and thus investigation on this field could help to 
understand the pathogenesis of COPD with various 
etiologies.  One study has reported a pathological 
examination of wood smoke-associated lung disease 
WSLD) and compared this to pathological features of 
smokers with COPD (60). In Mexico, patients with WSLD 
were non-smoking women who used wood for cooking for 
a median of 45 years. Dyspnea, airway obstruction, air 
trapping, increased airway resistance, pathological 
evidence of anthracosis, chronic bronchitis, centrilobular 
emphysema and pulmonary hypertension were present in 
most patients with WSLD. Importantly, there were no 
significant differences in the histopathological findings for 
emphysema, goblet cell hyperplasia, bronchial wall 
inflammation, airway smooth muscle hyperplasia, 
bronchiolitis or aspects of remodelling between patients 
with WSLD and smokers with COPD.  
It is evident that the effect of wood smoke exposure on 
lung health requires long-term exposure.  Acute exposure 
to wood smoke at a concentration normally found in a 
residential area with a high density of burning wood 
stoves causes only a mild transitory inflammatory 
response as determined by fractional exhaled nitric oxide 
(FENO), exhaled breath condensate (EBC) and nasal lavage 
(61). 
The innate immune response of cigarette smokers and 
subjects exposed to other environmental pollutants such as 
organic matter may also be similar.  Although not studied 
in relation to indoor biomass fuels, the response of subjects 
to inhaled LPS and of cells to in vitro challenge to LPS is 
similar between pig farmers who are constantly exposed to 
high levels of pathogen-associated molecular patterns 
(PAMPs) and cigarette smokers (62) LPS challenge in vivo 
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had no effect on markers of systemic inflammation 
including the expression of Th2 cytokines and Toll-like 
receptors TLR) in peripheral blood cells in smokers or 
farmers compared with the marked effects seen in control 
subjects.   
Animal models of wood smoke exposure also support a 
similar pathology to cigarette smoke-induced emphysema 
(63).  Long term exposure (up to 7 months) of guinea pigs 
to pine wood smoke showed alveolar mononuclear 
phagocyte and lymphocytic peribronchiolar inflammation, 
epithelial and smooth muscle hyperplasia, and pulmonary 
arterial hypertension. Mild to moderate emphysematous 
lesions were observed in wood smoke-exposed animals 
after 4 months. A higher percentage of whole blood 
carboxyhemoglobin (COHb) and elastolytic activity in 
bronchoalveolar lavage macrophages and lung tissue 
homogenates was also observed.  Increased collagen 
breakdown coincided with emphysematous changes as a 
result of enhanced MMP-2 and MMP-9 activity. 
Emphysema also correlated with enhanced apoptosis 
supporting a role for MMPs and apoptosis in emphysema 
secondary to wood smoke exposure.  Wood smoke extract 
can also directly induce apoptosis of human lung 
endothelial cells through an oxidative stress-mediated 
mechanism (64).  
Exposure of rats to wood smoke caused bronchiolitis, 
hyperplasia and hypertrophy of bronchiolar epithelial 
lining cells, edema, hyperplasia of lymphoid follicles, 
peribronchiolar and perivascular infiltration of 
polymorphonuclear cells, and mild emphysema after 15 
days.  All signs apart from emphysema got progressively 
worse with continued exposure (65). In addition, exposure 
of allergic rats to 2.5 months of low-levels of wood smoke 
exacerbated the inflammatory responses to ovalbumin in 
allergic rats (66). However, not all animal models of wood 
smoke exposure were able to demonstrate COPD-like 
responses (67).  
There may also be a link between indoor pollution and 
COPD due to cigarette smoking in that the fine particles 
produced by biomass fuels may exacerbate or enhance the 
immune response to cigarette smoking (68).  Indeed, 
exposure to biomass fuel smoke in a controlled indoor 
setting led to an altered response in COPD patients 
compared to control subjects.  At baseline, COPD patients 
had more CD14+ monocytes and neutrophils than healthy 
controls, but fewer CD3+ T cells and an altered gene 
expression profile in PBMCs (57/186 genes) with the 
majority being down-regulated in COPD.  In contrast, 
genes such as NF-B1, TIMP-1, TIMP-2 and Duffy were 
up-regulated in COPD subjects. After 4 hours exposure to 
biomass fuel smoke, monocyte levels decreased in the 
healthy subjects but not in the COPD subjects.  In addition, 
genes relating to immune and inflammatory responses and 
cell-cell signalling were differentially affected in the 
PBMCs of COPD subjects. 
 
Autoimmunity and emphysema 
The description of increased B-cell follicles in more 
advanced COPD (69) emphasized the possible importance 
of an autoimmune component in COPD pathology (27,59). 
Autoimmune diseases are characterised by circulating 
antinuclear antibodies (ANA) and these are found at 
greater levels in the serum of 25-30% of COPD patients (70, 
71). Initial reports also described that auto-antibodies 
against elastin (72) have not been consistently reproduced 
(73) although autoantibodies against other matrix 
components of the airway such as collagen V have been 
reported (74, 75).   
Serum autoantibodies against bronchial epithelial cells 
along with corresponding IgG and complement (C3) 
deposition (76) have also been observed in COPD lung. In 
addition, smoking is associated with high levels of class-
switched memory B-cells IgG versus IgA in healthy 
controls), blood and IgG memory B-cells in the lung. There 
was also a greater number of anti-decorin antibody-
producing cells in COPD patients compared with healthy 
controls (77). More recently, Packard and colleagues using 
an autoantigen array demonstrated that COPD patients 
express autoantibodies against a wide variety of self-
antigens which correlate with disease phenotype and 
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particularly with emphysema (78). Importantly, 
emphysematous patients produced autoantibodies of both 
higher titre and reactivity than those of control subjects.   
One possibility to account for these differences is that 
the autoantibodies are mainly directed against oxidative 
stress-modified self-proteins and that epitope spreading 
occurs to allow variable detection of autoantibodies against 
unmodified protein (27).  This study also reported 
autoantibodies against endothelial cells and deposition of 
activated complement in the vessels of COPD lung (27). 
This report confirmed earlier evidence for the presence of 
anti-endothelial autoantibodies in patients with COPD 
(79). An alternative explanation for the failure to 
consistently show elevated serum levels of anti-eleastin 
antibodies may be due to the fact that these antibodies are 
more easily detected as elevated in bronchoalveolar lavage 
fluid than in plasma (80). 
Ozone-exposed mice also exhibited increased antibody 
titres to carbonyl-modified protein, as well as activated 
antigen-presenting cells in lung tissue and splenocytes 
sensitized to activation by carbonyl-modified protein lung 
(27).  Similarly, cigarette smoke exposure in mice gives rise 
to the production of a humoral response against elastin, 
collagen and decorin proteins (81).  This autoimmune 
response was also accompanied by macrophage influx into 
the airway.  To date there are no studies that examine the 
expression of autoantibodies in either non-smoking COPD 
patients or in response to wood smoke exposure.  This is 
an area that needs additional research. 
 
Can a similar response to bronchodilators 
be expected in COPD patients whether due 
to cigarette smoke or indoor pollution? 
Patients with COPD are still commonly thought to 
show diminished acute bronchodilator responsiveness 
compared to asthmatics, and reversibility testing is 
sometimes proposed as a method of discriminating 
between asthma and COPD, despite previous evidence to 
the contrary (82). 
Therapeutic agents prevent and control symptoms, 
reduce exacerbations, increase exercise tolerance, and 
improve health status (83, 84). Long-acting β2-adrenergic 
agonists (LABAs, such as salmeterol) combine symptom 
control with improvement in lung function and provide 
clinically relevant improvements in health status. Inhaled 
corticosteroids (ICS) are recommended for the treatment of 
patients with a more severe disease and frequent 
exacerbations, and inhalation of the combination of LABAs 
and ICS is more effective in improving lung function and 
symptoms and reducing exacerbations than either drug 
alone (85, 86). Moreover, recently, it has been 
demonstrated that LABAs can enhance the anti-
inflammatory action of GCs. 
The acute bronchodilator responsiveness in patients 
with COPD has not been characterized rigorously in large 
cohorts. This is because determination of the response to a 
bronchodilator is influenced by physiological and 
methodological factors, including differences in baseline 
degree of airflow obstruction, diurnal and day-to-day 
variability in bronchomotor tone, dose and class of inhaled 
bronchodilator therapy, method of bronchodilator 
administration e.g. metered-dose inhaler with or without a 
spacer or solution nebuliser), dose of bronchodilator, and 
timing of post-bronchodilator spirometry. These responses 
may also be confounded by the presence of specific mast 
cell subtypes which may alter the response to 
bronchodilators (94). 
We and others have previously described the potential 
involvement of mast cells in the pathogenesis of lung 
diseases including COPD (87-89). Mast cells are thought to 
contribute to bronchoconstriction, mucus secretion, 
mucosal edema, bronchial hyperreactivity (BHR), 
inflammation, angiogenesis and airway remodelling in 
asthma (90-93). In particular, an increase in the number of 
airway smooth muscle (ASM) layer mast cells has been 
suggested to be related to asthmatic BHR (94). 
Bronchodilator responsiveness (BDR) has been shown to 
be related to BHR (95) and is probably based on similar 
underlying mechanisms.  In addition, we demonstrated in 
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an in vitro study that cigarette smoke medium CSM) 
stimulated the release of chemokines from mast cells in a 
noncytotoxic manner but did not induce mast cell 
degranulation (88).  
It is generally held that, by definition, airway 
obstruction in COPD is irreversible. However, significant 
BDR is in fact present in a large subgroup of patients with 
COPD, although they are mainly screened out from 
therapeutic studies (96, 97, ). Some investigators have 
suggested that this BDR feature in COPD is related to 
“asthma-like” pathology, i.e. an overlap syndrome (98, 
99)). A substantial number of COPD subjects have been 
shown to have BHR (100, 101) with a significant correlation 
between BDR and BHR (102). Recently, it has been shown 
that in COPD subjects without BDR, there was a positive 
relationship between mast cell density and better airway 
function (89). In this regard we were not able to rule out 
the role of eosinophils in BDR reaction since it has been 
shown that  high sputum eosinophil count did identify a 
subgroup of patients with COPD who respond to inhaled 
corticosteroids in terms of lung function. 
In summary, despite the heterogeneity across the 
selected studies, exposure to solid fuel smoke is 
consistently associated with COPD and chronic bronchitis.  
Women using biomass fuel for cooking typically spend 
about 40,000 hours and inhale a total volume of 25 million 
litres of polluted air during their lifetime (57). A recent 
meta-analysis has reported that the odds of COPD in 
biomass smoke exposed individuals is of a similar 
magnitude to that reported between tobacco smoking and 
COPD (57). The limited evidence available to date suggests 
that the pathology of biomass-induced and cigarette 
smoke-induced COPD are the same.  This suggests that the 
prognosis and response to inhaled β2-agonists and 
combination therapy should be similar in these groups of 
patients. We await the development of better anti-
inflammatory treatments for COPD in order to prevent the 
inexorable progression of disease seen in these patients.  
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